Pandemic Influenza H1N1 2009, Innate Immunity,and the Impact of Immunosenescence on Influenza Vaccine |
| |
Authors: | Samit R. Joshi Albert C. Shaw Vincent J. Quagliarello |
| |
Affiliation: | aDivision of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut;bDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut |
| |
Abstract: | Seasonal and pandemic strains of influenza have widespread implications for the global economy and global health. This has been highlighted recently as the epidemiologic characteristics for hospitalization and mortality for pandemic influenza H1N1 2009 are now emerging. While treatment with neuraminidase inhibitors are effective for seasonal and pandemic influenza, prevention of morbidity and mortality through effective vaccines requires a rigorous process of research and development. Vulnerable populations such as older adults (i.e., > age 65 years) suffer the greatest impact from seasonal influenza yet do not have a consistent seroprotective response to seasonal influenza vaccines due to a combination of factors. This short narrative review will highlight the emerging epidemiologic characteristics of pandemic H1N1 2009 and focus on immunosenescence, innate immune system responses to influenza virus infection and vaccination, and influenza vaccine responsiveness as it relates to seasonal and H1N1 pandemic influenza vaccines. |
| |
Keywords: | H1N1 Toll-like receptor innate immunity aging innate immunity TLR adjuvant immunosenescence elderly geriatric influenza vaccine |
|
|